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Abstract
Background Cathepsin K (CatK) is a widely expressed cysteine protease that has gained attention because of its enzymatic
and non-enzymatic functions in signalling. Here, we examined whether CatK-deﬁciency (CatK/) would mitigate injury-
related skeletal muscle remodelling and ﬁbrosis in mice, with a special focus on inﬂammation and muscle cell apoptosis.
Methods Cardiotoxin (CTX, 20 μM/200 μL) was injected into the left gastrocnemius muscle of male wild-type (CatK+/+) and
CatK/ mice, and the mice were processed for morphological and biochemical studies.
Results On post-injection Day 14, CatK deletion ameliorated muscle interstitial ﬁbrosis and remodelling and performance. At
an early time point (Day 3), CatK/ reduced the lesion macrophage and leucocyte contents and cell apoptosis, the mRNA
levels of monocyte chemoattractant protein-1, toll-like receptor-2 and toll-like receptor-4, and the gelatinolytic activity related
to matrix metalloproteinase-2/-9. CatK deletion also restored the protein levels of caspase-3 and cleaved caspase-8 and the
ratio of the BAX to the Bcl-2. Moreover, CatK deﬁciency protected muscle ﬁbre laminin and desmin disorder in response to
CTX injury. These beneﬁcial muscle effects were mimicked by CatK-speciﬁc inhibitor treatment. In vitro experiments demon-
strated that pharmacological CatK inhibition reduced the apoptosis of C2C12 mouse myoblasts and the levels of BAX and
caspase-3 proteins induced by CTX.
Conclusions These results demonstrate that CatK plays an essential role in skeletal muscle loss and ﬁbrosis in response to
CTX injury, possibly via a reduction of inﬂammation and cell apoptosis, suggesting a novel therapeutic strategy for the control
of skeletal muscle diseases by regulating CatK activity.
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Introduction
Age-related loss of skeletal muscle mass and function can
result in decreased quality of life.1 The causes of age-
associated muscle disease (i.e. sarcopenia) are multifactorial
and include biological and environmental factors.1–3 Skeletal
muscle cell apoptosis associated with various injuries has
been shown to contribute to muscle remodelling and ﬁbrosis
in aged animals and humans.3 The pathogenesis of
injury-associated skeletal muscle disorder involves extensive
extracellular matrix (ECM) remodelling, which requires the
participation of extracellular proteases.1 The matrix metallo-
proteinase (MMP) family has been shown to participate in
muscle disease inception and progression.4–6 However,
genetic and pharmacological interventions aimed at MMP
family members resulted in incomplete prevention of muscle
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remodelling and ﬁbrosis,7–9 suggesting that other proteases
may also contribute to such remodelling in injury-related
muscle disorders.
The cathepsins known as cysteine proteases were discov-
ered in the second half of the 20th century.10 In humans,
the cathepsin family consists of 11 members [i.e. cathepsin
K (CatK), CatS, CatL, CatB, etc.].11 Initially, cathepsins were
recognized to function as scavengers for protein recycling in
lysosomes and endosomes of mammalian cells under physio-
logical and pathological conditions.10–15 However, the recog-
nition of the cysteinyl cathepsins led to the exploration of
their functions in metabolic and inﬂammatory cardiovascular
disorders.16–20 Like the members of the MMP family, most of
the cathepsins have been shown to be regulatory
exoproteases that are widely expressed in various tissues or
cells by inﬂammatory cytokines and growth factors.21–24 CatK
is one of the most potent of the mammalian elastases and
collagenases.25 Previous studies have demonstrated that
CatK expression is increased in the atherosclerotic lesions of
animals and humans.26,27 In our own previous report, we
clearly showed that CatK deletion confers resistance to
carotid artery injury via a reduction in the levels of toll-like
receptors (TLR)-2/-4.28 Moreover, CatK has been shown to
control ischaemia-induced neovascularization via the modu-
lation of Notch-1 activation and a downstream signalling
pathway.29 Laboratory studies revealed that cathepsins are
involved in apoptosis and proliferation in cancer and
immune-inﬂammatory cells. Comprehensive review articles
have highlighted the functional signiﬁcance of CatK in
growth-related tumours and cardiovascular disease.13,30
Despite this body of research, however, there is limited infor-
mation about the role of CatK in age-related and injury-
related skeletal muscle disorders.
In the present study, we used CatK-deﬁcient (CatK/)
mice and an experimental skeletal injury model to test our
hypothesis that CatK activity controls muscle remodelling
and dysfunction in response to injury.
Materials and methods
Antibodies and reagents
The following commercially available antibodies were used:
Bcl-2 (#2870), BAX (#2772), cleaved caspase-8 (#9429),
cleaved caspase-3 (#9661), and caspase-3 (#9662) (all from
Cell Signaling Technology, Beverly, MA); CatK (#3368;
BioVision, Milpitas, CA); CD45 (clone 30-F11; Biolegend, San
Diego, CA); CD68 (clone KP1, ab955; AbCam, Cambridge,
UK); Laminin-5 (BS-7713R; Bioss, Woburn, MA); Desmin
(Clone 33; Dako, Carpinteria, CA); Zenon rabbit and mouse
IgG labelling kits (Molecular Probes, Eugene, OR); and GAPDH
(G8795) as loading controls (Sigma-Aldrich, St. Louis, MO).
Cardiotoxin (CTX) was from Sigma-Aldrich (Naja pallida,
L8102, Latoxan). CatK inhibitor (ONO-KK1-300-01) was pro-
vided by Ono Pharmaceutical (Osaka, Japan).
Pentobarbital sodium was from Dainippon Pharmaceutical
Co. (Osaka, Japan), and the RNA PCR Core kit was from
Applied Biosystems (Foster City, CA). The RNeasy Fibrous
Tissue Mini-Kit was from Qiagen (Hilden, Germany). The In
Situ Cell Death Detection Kit (reference no. 11684795910)
was from Roche Diagnostics (Mannheim, Germany). C2C12
mouse myoblasts were obtained from the American Type
Culture Collection (Manassas, VA). Dulbecco’s modiﬁed Eagle
medium (DMEM) was from GIBCO Life Technologies (Grand
Island, NY). Horse serum was also from GIBCO Life
Technologies (Auckland, New Zealand).
Animal care and use
The male CatK/ and wild-type (C57BL/6, CatK+/+) litter-
mates used in this study had approximately the same body
weights (22–24 g).28 The animals were housed in a room with
a controlled temperature (22°C ± 2°C) and a 12 h light–dark
cycle, with ad libitum access to food and water. All mouse
experiments were performed with the approval of the
Institutional Animal Care and Use Committee at Nagoya
University and were in accordance with the U.S. National
Institutes of Health (NIH) Guide for the Care and Use of
Laboratory Animals.
Model of the skeletal muscle injury and tissue
collection
For evaluation of the role of CatK in muscle remodelling,
10 ± 2-week-old CatK+/+ and CatK/ mice were used. The
hair of both legs was shaved, and CTX (20 μM/200 μL) was
injected into the left gastrocnemius muscle. For a separate
speciﬁc CatK inhibitor experiment, CatK+/+ mice that received
an injection of the CTX (20 μM/200 μL) were randomly
assigned to one of the three groups and administered (by oral
gavage) vehicle (200 μL of 0.5% carboxymethylcellulose;
Cont) or a low dose or high dose of a CatK inhibitor (ONO-
KK1-300-01: 3 mg/kg, low-dose CatK inhibitor; 30 mg/kg,
high-dose CatK inhibitor ; Ono Pharmaceutical) twice daily
from 2 days before the injury to 14 days after the injury.
At the indicated time points, all animals were anaesthe-
tized with an intraperitoneal injection of pentobarbital
sodium (50 mg/kg), and the tissue (muscles) and arterial
blood samples were collected. For the biological analysis,
the skeletal muscle was isolated and kept in RNAlater solu-
tion (for the gene assay) or liquid nitrogen (for the protein
assay). For the morphological analysis, after being immersed
in ﬁxative at 4°C, the skeletal muscles were embedded in
optimal cutting temperature compound (Sakura Fine-
technical, Tokyo) and stored at 20°C. After the blood was
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poured into an EDTA-2Na blood collection tube (VenojectII;
Terumo, Kakamigahara, Japan), it was centrifuged, and the
plasma was collected and stored at 80°C.
Evaluation of muscle endurance capacity
A motorized rodent treadmill (S-Con Mini-Z: Tokyo Engineer-
ing, Tokyo) was used to determine the endurance capacity for
running, as described previously.31 In the preliminary training
sessions, mice at Day 1 before the CTX injection were made
to run on the treadmill at an inclination of 0° as follows:
warm-up (5 min), 7 m/min; exercise (35 min), 17 m/min; cool
down (5 min), 7 m/min. For the measurement of endurance
capacity, the mice at Days 3 and 14 after CTX injury were
placed on the treadmill, and the warm-up was started at
6 m/min with the treadmill’s tilt angle at 0°. After 5 min,
the tilt angle of the treadmill was set to 10°, and the speed
was gradually increased by 2 m/min every 2 min until
reaching the maximum speed of 20 m/min and then
maintained at the maximum speed.
During the running period, the mouse was prevented from
resting by a shock bar placed behind the treadmill, which was
set at 20 V. The calculations of the running distance and
workload were ﬁnished when the mouse stopped moving
for >10 s. The running distance was calculated as a product
of the running time and speed. The workload in the vertical
direction was calculated with consideration for the weight
of the mouse (=weight × gravitational acceleration × mileage
in the vertical direction). All items are expressed as the ratio
of the observed values to the data obtained on Day 0 before
the CTX injection.
Evaluation of grip strength
We also studied the animals’ grip strength by using a small
animal grip strength meter (Columbus, Largo, FL) as de-
scribed previously.31 The forelimb of the mouse was placed
on the limb grip of the meter, and its tail was gently pulled
in the opposite direction. We measured the maximum value
of the grip force that the mouse exerted before it released
its grip. The grip strength was measured over ﬁve times for
each mouse on Days 0, 3, and 14, and the values were
averaged as the grip strength value for each of these days.
To exclude the inﬂuence of exercise, the mice that
underwent the grip strength and endurance examinations
were not subjected to the histological or biological analyses.
Quantitative real-time gene expression assay
Total RNA was extracted from the tissue, or the cell extracts
with an RNeasy Fibrous Tissue Mini-Kit in accord with the
manufacturer’s instructions. The mRNA was reverse-
transcribed to cDNA with an RNA polymerase chain reaction
(PCR) Core kit. Quantitative gene expression was studied
using an ABI 7300 PCR system with Universal PCR Master
Mix (Applied Biosystems). All experiments were performed
in triplicate. The sequences of the primers used for CatK,
CatS, CatL, MMP-2, MMP-9, tissue inhibitor of MMP-1
(TIMP-1), TIMP-2, TLR-2, TLR-4, monocyte chemoattractant
protein-1 (MCP-1), tumour necrosis factor-alpha (TNF-α),
and GAPDH genes are shown in Table S1. The transcription
of target genes was normalized to GAPDH.
Morphometry and immunohistochemistry analyses
Serial cross-cryosections (4 μm thick) were collected at the
injured regions of the skeletal muscle at a rate of 3–4 sections
every 40 μm. The sections at Day 3 after injury were used to
evaluate the inﬂammation and cell apoptosis in response to
injury. For the immunohistochemistry, corresponding sections
on separate slides were treated with mouse monoclonal
antibodies against CD45 for leucocytes or CD68 for macro-
phages (1:50 for each).32 The sections were then visualized
with an ABC substrate kit (SK-4400; Vector Laboratories,
Burlingame, CA) in accordwith themanufacturer’s instructions.
Apoptotic staining was performed as follows: the sections
were subjected to terminal deoxynucleotidyl transferase-
mediated dUTP nick end labelling (TUNEL) using a Fluorescein
In Situ Cell Death Detection Kit (Sigma-Aldrich). The sections
at Day 14 were used to examine muscle remodelling and
ﬁbrosis. Masson’s trichrome staining for ﬁbrosis was per-
formed as described previously.33 The slides of the muscles
and the cells were mounted in glycerol-based Vectashield
medium (Vector Laboratories) containing the nucleus stain
4,60-diamidino-2-phenylindole.
For quantiﬁcation of the positive cell staining, we took six
to seven images for one section using a ×20 objective, and
we counted the numbers of CD45+, CD68+, and TUNEL+ cells.
For the quantiﬁcations of muscle ﬁbres and ﬁbrosis, we took
seven to nine images at 90 000 μm2 for one section using a
×20 objective, and we measured cross-sectional area of a
muscle ﬁbre with the central nucleus and the volumes of
interstitial ﬁbrosis in this ﬁeld by using a microscope
(BZ9000; Keyence, Osaka, Japan). For negative controls, the
primary antibodies were replaced with non-immune immu-
noglobulin G or Zenon-labelled rabbit or mouse IgG.
Immunoﬂuorescence
To examine the changes in the muscle ﬁbre structural proper-
ties and healing capacity, double immunoﬂuorescence
labelling of the laminin and desmin was performed as
described previously.31 In brief, the muscle sections were
treated with a rabbit polyclonal antibody to laminin-5 and a
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mouse monoclonal antibody to desmin (1:100 for each).
Then, the sections were visualized using Zenon rabbit and
mouse IgG labelling kits (1:200) according to the manufac-
turer’s instructions. Staining sections were visualized with a
BZ-X700 microscope (Keyence, Osaka, Japan) using ×20 or
×40 objectives. We measured the average intensity of desmin
protein expression for six ﬁbres in one section by using the
Image J software program.
Gelatin zymography
Gelatin zymography was performed as described previ-
ously.34 Each sample was mixed with an equal volume of
sample buffer without a reducing agent. Forty micrograms
of each muscle tissue protein extract was then loaded onto
a 10% SDS–polyacrylamide gel containing 1 mg/mL gelatin
as a substrate. After electrophoresis, the gels were washed
twice with 2.5% Triton X-100 and then incubated overnight
at 37°C with substrate buffer (pH 8.0, 50 mM NaCl, 50 mM
Tris, and 10 mM CaCl2). Finally, the gels were stained with
Coomassie Brilliant blue and bleached to reveal the
gelatinolytic activities as clear bands against a blue-stained
background. Quantitative data were obtained by
densitometry.35
Biochemical analyses
To evaluate the muscle and cell injuries, the lactate dehydro-
genase (LDH) levels in mouse plasma on Day 3 after injury
and the C2C12 cell-conditioned medium after treatment with
CTX at the indicated concentrations for 24 h were measured
at a commercial laboratory (SRL, Tokyo, Japan).
Simple western analysis
Simple western analysis is a well-known protein detection
method used in conjunction with the western blotting
assay.36 WES™ instrumentation is one of the SimpleWestern™
systems provided by ProteinSimple. We performed the WES™
analysis according to the ProteinSimple user manual. In brief,
samples were adjusted to an appropriate protein concentra-
tion in 4 μL with 0.1% sample buffer and further diluted 1:4
by adding 1.0 μL of ×5 ﬂuorescent master mix (containing
20 μL of 10× sample buffer and 20 μL of 400 mM DTT). Five
microlitres of each ﬁnal sample and Biotin ladder (containing
16 μL of deionized water, 2 μL of 10× sample buffer, and 2 μL
of 400 mM DTT) was heated at 95°C for 5 min, added to a 1:1
mixture of luminol-S and peroxide (150 μL), and stored in ice
until use. The primary antibodies (i.e. anti-cleaved caspase-8,
anti-caspase-3, anti-BAX, anti-Bcl-2, and anti-GAPDH) were
diluted 1:50 to 1:100 with antibody diluent II, and the
secondary antibody was used without dilution. After applying
the appropriate samples and reagents to each well, we
centrifuged the plate for 5 min at 150 g at room temperature,
and then set it and a capillary cartridge in WES™. The data
obtained by SimpleWestern™ assay were automatically
analysed to determine the molecular weight of the detected
protein and to subject it to quantitative analysis using the
attached Compass software. In addition, we also performed
a general western blotting assay to evaluate the levels of
cleaved caspase-3, caspase-3, and GADPH proteins in the
muscles.
Cell culture
C2C12 cells were grown in DMEM containing 10% foetal
bovine serum and antibiotics at 37°C with 5% CO2. At conﬂu-
ence, the myoblasts were induced to fuse by changing the
medium to medium containing 2% horse serum (called ‘dif-
ferentiation medium’ herein) as described previously.37 After
5–6 days of differentiation, when the myoblasts had length-
ened, fused, and become multinucleated myotubes, the
differentiated C2C12 cells were cultured with serum-free
DMEM for 6 h. Following pre-treatment with a CatK-speciﬁc
inhibitor (ONO-KK1-300-01) at the indicated concentrations,
the cells were cultured in the presence or absence of CTX
at the indicated concentrations and time points, and the
conditioned medium and the cells were subjected to the
biological analysis.
TUNEL staining
After the differentiation of C2C12 cells, the cells were
cultured in serum-free DMEM containing 0.5 μM CTX in the
presence and absence of the CatK inhibitor ONO-KK1-300-
01 for 24 h and then subjected to TUNEL staining as described
previously.31 The apoptotic cells in the muscles were also
evaluated by TUNEL staining.
Collagenase assay
After the differentiation of C2C12 cells, the cells were
cultured in serum-free DMEM containing 0.5 μM CTX in the
presence and absence of the CatK inhibitor ONO-KK1-300-
01 for 24 h and then subjected to collagenase assay used
FITC-Bovine Type I Collagen (Cat: #4001; Chondrex, Inc.,
Redmond, WA) as described previously.26
Statistical analysis
The data are expressed as the mean ± standard deviation.
Student’s t-test (for comparisons between two groups) or
one-way analysis of variance (for comparisons of three or
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more groups) followed by Tukey post hoc tests was used for
the statistical analyses. The muscle performance data were
subjected to two-way repeated-measures analysis of variance
and Bonferroni post hoc tests. SPSS software ver. 17.0 (SPSS,
Chicago, IL) was used. P values <0.05 were considered
signiﬁcant.
Results
The changes in cathepsin expression in response to
cardiotoxin injection
Figure S1A illustrates the severe muscle damage (e.g. oedema,
haemorrhage, and muscle ﬁbre loss). At ﬁrst, we examined the
inﬂuence of CTX on cathepsin family expression. We isolated
total RNA from the muscles at the indicated time points after
injury and used it in a quantitative real-time gene assay to de-
termine the CatK, CatS, and CatL mRNA levels. We observed
that the CatK mRNA levels were signiﬁcantly increased in
CTX-injured muscles throughout the follow-up period and
reached a 50-fold peak at Day 3 after injury (Figure S1B). Sim-
ilarly, the CatS and CatL mRNA levels had signiﬁcantly increased
between 3 and 7 days after injury, with the highest expression
occurring at Day 3 (Figure S1B). We also observed that the in-
jured muscles had increased levels of MMP-2 and MMP-9
mRNAs and increased levels of their endogenous inhibitor
(TIMP-1 and TIMP-2) mRNAs compared with before the injury
(Figure S1C,D). The gelatin zymography revealed that the
gelatinolytic activities of MMP-2 and MMP-9 were increased
in the injured muscles compared with those in the non-injured
muscles at Day 3 after the CTX injection (Figure S1E).
Cathepsin K deﬁciency protects against
cardiotoxin-induced muscle damage
To explore whether CatK modulates muscle remodelling and
ﬁbrosis in response to injury, we created a skeletal muscle
CTX injury model using CatK+/+ and CatK/ mice to monitor
Figure 1 CatK deﬁciency (CatK/) alleviated the cardiotoxin-induced skeletal muscle remodelling and ﬁbrosis at Day 14 after injury. (A) Representa-
tive images of haematoxylin and eosin (H&E) and Masson’s trichrome staining of the injured gastrocnemius muscle sections of wild-type (CatK+/+) and
CatK
/
mice. Scale bar, 100 μm. (B, C) Quantitative data showing the cross-sectional area of a muscle ﬁbre and interstitial ﬁbrosis (90 000 μm2). (D, E)
Representative immunoﬂuorescence images and quantitative data for the intensity of desmin protein expression in CatK+/+ and CatK/ mice at Day
14 after injury. Scale bar, 50 μm. Results are the mean ± SD (n = 5–6). Signiﬁcance was estimated using Student’s t-test (*P < 0.05, **P < 0.01).
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muscle morphological and functional changes in the gastroc-
nemius muscles. On post-injection Day 14, the histological
analysis revealed that the CatK/ mice had better preserved
muscle ﬁbre size (450 ± 115 vs. 308 ± 52 μm2, P < 0.05) and
lower levels of interstitial ﬁbrosis (30661 ± 5077 vs.
45081 ± 4159 μm2, P < 0.01) compared with the wild-type
(CatK+/+) mice, respectively (Figure 1A and 1C). Desmin is
known to be an intermediate ﬁlament protein that is highly
expressed in immature muscle ﬁbre during foetal life and re-
generation.38 To further visualize the healing process, we per-
formed double immunoﬂuorescence labelling with desmin
and laminin-5. As shown in Figure 1D and 1E, CatK/ mice
exposed to CTX injury had markedly higher intracellular in-
tensity of desmin expression (32.9 ± 3.4 vs. 12.8 ± 1.4,
P < 0.01) than CatK+/+ mice, which suggests that CatK dele-
tion preserved the structural properties of the muscle ﬁbre
and restored tissue healing in response to CTX injury.38 The
quantitative analysis of muscle performance demonstrated
that except grip strength, CatK deletion prevented CTX-
induced impairment of running distance and workload at
Day 14 after injury (Figure 2A and 2B). We also observed that
the running time and distance were better preserved in the
CatK/ mice compared with those in the CatK+/+ mice at
Day 14 after injury (Figure 2C and 2D), indicating that CatK
deﬁciency ameliorates muscle remodelling and dysfunction
because of CTX injury.
Cathepsin K deﬁciency mitigated the
cardiotoxin-induced cell apoptosis
The TUNEL staining showed marked TUNEL+ apoptotic cells
in the injured muscles of CatK+/+ mice on Day 3 after the
CTX injection, and this change was prevented by CatK de-
letion (Figure 3A and 3B). Plasma LDH levels have often
been used to predict muscle injury in humans and ani-
mals.39 To further examine the difference in muscle injury,
the plasma LDH levels were analysed by enzyme-linked im-
munosorbent assay. The quantitative biological analysis re-
vealed signiﬁcantly lower levels of plasma LDH from the
CatK/ mice compared with that from the CatK+/+ mice
(Figure 3C). To examine the possible participation of CatK
in the protection against CTX-induced cell apoptosis, we
assessed the levels of pro-apoptotic and anti-apoptotic
molecules by performing a simple western blotting analy-
sis. As anticipated, the levels of caspase-3, cleaved
caspase-8, the ratio of cleaved caspase-3 to caspase-3,
and the ratio of BAX to Bcl-2 proteins were all signiﬁcantly
lower in the injured muscles of CatK/ mice compared
with those in the CatK+/+ mice at Day 3 after injury
(Figure 3D–3G, Figure S2A,B). CatK deﬁciency thus exhibited
a muscle beneﬁt via the reduction of CTX-induced cell
apoptosis in the mice.
Figure 2 CatK deﬁciency prevented cardiotoxin-induced muscle dysfunction. (A) Grip strength was measured. (B) Workload in the vertical di-
rection was calculated as described in the Materials and Methods. (C, D) Running time and distance were calculated from the results of the
running time and speed. All items are expressed as the ratio of observed values to the data obtained on Day 1 before cardiotoxin injection.
Results are the mean ± SD (n = 6). *P < 0.05, **P < 0.01 vs. the corresponding controls by two-way repeated-measures analysis of variance
and Bonferroni post hoc tests.
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Cathepsin K deﬁciency ameliorated inﬂammatory
actions in response to cardiotoxin
It is known that inﬂammation plays a fundamental role in all
stages of wound healing after injury. As inﬂammation activa-
tion seemed to be tightly associated with increased CatK
expression, we extended our examination to inﬂammatory
cell inﬁltration at Day 3 after the CTX injection. The results
demonstrated that CatK deletion ameliorated the macro-
phage and leucocyte inﬁltrations (CD68: 46 ± 10 vs.
111 ± 13; CD45: 94 ± 17 vs. 207 ± 13, cell numbers:
P < 0.01 for each) (Figure 4A–4C). The quantitative real-time
PCR data demonstrated that CatK deletion decreased the
levels of inﬂammatory genes such as TNF-α, TLR-2, TLR-4,
and MCP-1 in injured muscles compared with CatK+/+ mice
(Figure 4D–4G), suggesting that CatK deﬁciency-mediated
anti-inﬂammatory actions may contribute to the muscle ben-
eﬁt in this CTX injury model.
To further examine the consequence of CatK silencing on
other cathepsin family members, we analysed the total
RNA extraction of the muscles in a gene expression assay.
The results indicated that CatK deletion had no effect on
the CatS or CatL expression not only in non-injured muscles
but also in injured muscles (Figure S3A). However, com-
pared with those of CatK+/+ mice, the injured muscles of
CatK/ mice had decreased levels of MMP-2 and MMP-9
as well as their endogenous inhibitor TIMP-1 and TIMP-2
genes (Figure S3B,C). Consistently, we observed that CatK
deﬁciency reduced the gelatinolytic net activities of MMP-
2 and MMP-9 (Figure S3D,E).
Pharmacological cathepsin K inhibition suppressed
muscle remodelling and apoptosis
Figure 5A shows non-injured and injured muscle ﬁbre size
(haematoxylin and eosin) and ﬁbrosis (Masson’s trichrome)
of mice treated with vehicle (CONT), low-dose CatK inhibitor,
and high-dose CatK inhibitor. Similarly to the CatK deletion,
the pharmacological inhibition of CatK with ONO-KK1-300-01
preserved the muscle ﬁbre size and the intracellular intensity
of desmin expression and reduced the interstitial ﬁbrosis in a
dose-dependent manner (Figure 5B). Similarly, it also
prevented cell apoptosis in injured muscles in a dose-
Figure 3 CatK deletion mitigated cardiotoxin-induced apoptosis. (A, B) Representative images of terminal deoxynucleotidyl transferase dUTP nick end
labelling (TUNEL) immunoﬂuorescence and combined quantitative data show the numbers of TUNEL+ apoptotic cells in the injured gastrocnemius of
wild-type (CatK+/+) and CatK deﬁciency (CatK/) mice at Day 3 after cardiotoxin injection. (C) CatK deletion reduced the plasma lactate dehydrogenase
(LDH) level. (D–G) Representative images of simple western blots and the combined quantitative data show the levels of caspase-3 and cleaved cas-
pase-8 proteins and the ratio of BAX protein to Bcl-2 protein in the injured muscles of CatK+/+ and CatK/ mice. Results are the mean ± SD (n = 3–4).
*P < 0.05, **P < 0.01 vs. the corresponding control groups by Student’s t-test or one-way analysis of variance followed by Tukey post hoc tests.
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dependent manner (Figure 6A and 6B). Consistently, the CatK
inhibition suppressed plasma LDH levels (Figure 6C). Both
doses of CatK inhibitor reduced the expression of CatK protein
in the injured muscles (Figure 6D and 6E). Moreover, CatK in-
hibition improved the changes in the levels of caspase-3,
cleaved caspase-8, the ratio of cleaved caspase-3 to caspase-
3, and the ratio of BAX to Bcl-2 in a dose-dependent manner
(Figure 6D and 6F–H, Figure S2C,D). Thus, CatK inhibition also
exhibited a protective effect against CTX.
Cathepsin K inhibition mitigated the inﬂammatory
response to cardiotoxin
Representative immunostaining and the related quantitative
analysis demonstrated that the numbers of inﬁltrated macro-
phages and leucocytes were lower in the injured muscles of
the CatK+/+ mice administered a CatK inhibitor compared
with those of the non-treated control mice (Figure 7A–C). In-
terestingly, compared with the control mice, the CatK
inhibition also ameliorated the levels of TLR-2, TLR-4, TNF-α,
and MCP-1 mRNAs in the injured muscles of the CatK+/+ mice
(Figure 7D–G). Thus, the CatK inhibition-mediated anti-
inﬂammatory effects might have contributed to the muscle
protective actions in this mouse CTX injury model.
We next performed gene expression assays to examine
the effects of CatK inhibition on the cathepsin and MMP
gene expressions. Although there were no changes in the
CatS or CatL gene levels in the non-injured or injured mus-
cles among the three experimental groups, we observed
that CatK inhibition exerted a reduction of the CatK mRNA
expression of the injured muscles in a dose-dependent man-
ner (Figure S4A,B). Real-time PCR data showed that the
levels of the MMP-2/-9 and TIMP-1/-2 genes were lower
in the CatK+/+ mice that underwent CatK inhibitor treatment
in a dose-dependent manner (Figure S4C,D). Consistently,
the quantitative gelatin zymography assays revealed that
CatK inhibition suppressed the levels of MMP-2 and MMP-
9 gelatinolytic activities in the injured muscles of the
CatK+/+ mice (Figure S4E,F).
Figure 4 CatK deﬁciency (CatK/) ameliorated inﬂammatory actions in the injured muscles at Day 3 after cardiotoxin injection. (A) Representative
images of the immunostaining using CD68 antibody (for inﬁltrated macrophages) and CD45 antibody (for inﬁltrated leucocytes) in the injured gastroc-
nemius sections of wild-type (CatK+/+) and CatK/ mice. Scale bars: A, 50 μm; B, 25 μm. (B, C) Quantitative data for CD68-positive and CD45-positive
cell numbers. (D–G) Quantitative real-time polymerase chain reaction data show the levels of TLR-2, TLR-4, TNF-α, and MCP-1 in the non-injured and
injured gastrocnemius muscles of CatK+/+ and CatK/ mice. *P< 0.05, **P< 0.01 vs. the corresponding control groups by Student’s t-test or one-way
analysis of variance followed by Tukey post hoc tests.
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Cathepsin K inhibition mitigated impaired muscle
performance induced by cardiotoxin
We also investigated whether CatK inhibition could im-
prove CTX-induced muscle dysfunction at the indicated
time points. As expected, we observed that the muscle
performance (i.e. grip strength and change rate of work-
load, running time, and distance) was preserved in the
CatK+/+ mice subjected to CatK inhibitor treatment com-
pared with that in the control CatK+/+ mice at Day 14 after
injury (Figure S5).
Cathepsin K inhibition prevented
cardiotoxin-induced C2C12 cell injury
Figure 8A shows the morphological changes of the differen-
tiated C2C12 mouse myoblasts cultured in the presence and
absence of CTX (0.5 μM) and CTX + CatK inhibitor ONO-KK1-
300-01 (25 μM, CTX + CatK-I). As anticipated, CatK inhibition
suppressed the levels of conditioned medium LDH in
response to CTX (Figure 8B). We also observed that CatK
inhibition prevented CTX-induced C2C12 cell apoptosis
(Figure 8C). The western blotting assays showed that CatK
inhibition improved the changes in the levels of BAX and
caspase-3 proteins as well as the CatK protein levels
(Figure 8D and 8E), indicating that CatK inhibition can pro-
tect against differentiated C2C12 apoptosis via a reduction
of apoptosis-related targeted protein expressions. In addi-
tion, we observed that CTX stimulated CatK gene expression
in a time-dependent and dose-dependent manner, whereas
the serum-free medium had no effect on CatK gene expres-
sion (Figure S6). Moreover, quantitative collagenasse assay
revealed that CatK inhibitor signiﬁcantly suppressed CTX-
induced collagenolytic activity (14 896 ± 228 vs.
15 527 ± 246 intensity, P < 0.01).
Figure 5 Cat K inhibition alleviated cardiotoxin-induced skeletal muscle remodelling and ﬁbrosis at Day 14 after injury. (A) Representative image of
haematoxylin and eosin (H&E) and Masson’s trichrome staining of the injured gastrocnemius sections of the mice treated with vehicle (200 μL of
0.5% carboxymethylcellulose; CONT mice) or with a low dose or high dose of CatK inhibitor [ONO-KK1-300-01: 3 mg/kg, low-dose CatK inhibitor
(LKI) mice; 30 mg/kg, high-dose CatK inhibitor (HKI) mice] at Day 3 after injury. Scale bar, 100 μm. (B, C) Quantitative data showing the cross-sectional
area of a muscle ﬁbre and interstitial ﬁbrosis (90 000 μm2). (D, E) Representative immunoﬂuorescence images and quantitative data show the intensity
of desmin protein expression in the three groups. Scale bar, 50 μm. Results are the mean ± SD (n = 6). *P < 0.05, **P < 0.01 vs. the controls by one-
way analysis of variance followed by Tukey post hoc tests.
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Discussion
Skeletal muscle apoptosis has been shown to participate in
muscle weakness and wasting in response to injury. The
identiﬁcation of novel targets to prevent maladaptive skele-
tal muscle remodelling and ﬁbrosis will contribute to thera-
peutic strategies to pre-empt muscle mass wasting and
dysfunction in response to various injuries. The signiﬁcant
ﬁnding of the present study is that mice lacking the CatK
gene were resistant to acute CTX injury-induced skeletal
muscle loss and remodelling and the decline in muscle
strength. At the molecular level, CatK deletion reduced
CTX-induced TLR-2/-4 and their downstream inﬂammatory
gene expressions as well as inﬂammatory cell inﬁltrations
(macrophages and leucocytes) and changes in apoptosis-
related molecules (i.e. caspase-3, cleaved caspase-3, cleaved
caspase-8, and the ratio of BAX to Bcl-2). Our pharmacolog-
ical intervention targeting CatK also resulted in a skeletal
muscle protective action via the reduction of inﬂammation
and cell apoptosis. In vitro, the speciﬁc CatK inhibitor atten-
uated the apoptosis of differentiated C2C12 muscle cells
associated with the reductions of caspase-3 and BAX
proteins. To the best of our knowledge, this is the ﬁrst
study to provide evidence that genetic and pharmacological
interventions targeting CatK confer skeletal muscle protec-
tion against acute CTX injury.
Cysteinyl cathepsins can degrade the basement membrane
and surrounding ECM of cardiovascular walls.13–15 Cathepsin
family members such as CatK and CatS have been shown to
play a critical role in metabolic and inﬂammatory cardiovas-
cular disorders.15–17 Several clinical studies reported that
there is relationship between plasma CatK levels and cardio-
vascular disease stages and progression.18–20 Our research
and studies by other groups have demonstrated the in-
creased expression and activity of CatK in cardiovascular tis-
sues in response to various injuries.15–17 The ability of CTX
Figure 6 Pharmacological CatK inhibition mitigated apoptosis in the injured muscles of CONT (vehicle), LKI (low-dose CatK inhibitor), and HKI (high-
dose CatK inhibitor) mice at Day 3 after injury. (A, B) Representative images of terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL)
immunoﬂuorescence and combined quantitative data show the numbers of apoptotic cells in the injured gastrocnemius of the three experimental
groups (n = 6). (C) CatK inhibition suppressed the plasma lactate dehydrogenase (LDH) levels in response to cardiotoxin injury in a dose-dependent
manner (n = 6). (D–H) Representative images of simple western blots and combined quantitative data show the levels of caspase-3 and cleaved cas-
pase-8 proteins and the ratio of BAX protein levels to Bcl-2 protein levels in the injured muscles of the three experimental groups (n = 3). Results are
the mean ± SD. *P < 0.05, **P < 0.01 vs. the controls by one-way analysis of variance followed by Tukey post hoc tests.
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injury to increase CatK expression and activity probably
contributed to the muscle repair under our experimental con-
ditions. In agreement with reports that CatK deletion reduced
cardiovascular remodelling in response to various inju-
ries,24,28 we observed that skeletal muscle loss and ﬁbrosis
and dysfunction after injuries are mitigated by CatK/. Our
present ﬁndings showed that a pharmacological intervention
targeting CatK also exhibited beneﬁcial effects on skeletal
muscle under the same experimental conditions. Collectively,
these observations suggest that CatK may act as a key player
to modulate skeletal muscle remodelling, ﬁbrosis and dys-
function in response to CTX injury.
The engagement of TLRs on the cell surface by their
speciﬁc ligands leads to an increase in the expressions of
inﬂammatory chemokines and cytokines (e.g. MCP-1,
interleukin-1β, and TNF-α).40–42 In the present study, the in-
jured muscles of CatK/ mice contained much lower levels
of TLR-2 and TLR-4 genes as well as TNF-α and MCP-1 genes
compared with the control CatK+/+ mice. CatK deletion re-
tarded the macrophage accumulation of the injured skeletal
muscle tissues. The pharmacological inhibition of CatK also im-
proved the inﬂammation-related expressions of those genes
and the inﬂammatory cell inﬁltration to the CTX injury in the
CatK+/+ mice. Our previous study demonstrated a genetic or
pharmacological inhibition of CatK ameliorated injury-related
vascular remodelling via the reduction of TLR-2/-4-mediated
inﬂammatory in the carotid artery.28 Thus, CatK/ appears
to mitigate macrophage inﬁltration and activation and inﬂam-
matory chemokine expression in injury-stress states through
its ability to reduce TLR-2 and TLR-4 expressions.
It is well established that among the members of the MMP
family, MMP-2 and MMP-9, which are expressed and
secreted mainly by inﬂammatory cells (i.e. macrophages
and leucocytes), participate in muscle dystrophy and ECM
remodelling.4–6 The ability of CTX injury to also increase both
of these genes and their activities is likely to have contributed
to the muscle interstitial ﬁbrosis and dysfunction observed in
the CTX-treated mice in the present study. Data from the
present and previous studies show that CatK inhibition by a
genetic or pharmacological approach ameliorates not only
MMP-2 and MMP-9 expression and activities but also
targeted tissue/organ damage and dysfunction under condi-
tions of ischaemic, surgical, and CTX injuries.28,29 TLR-2 and
TLR-4 have been shown to modulate monocyte/macrophage
activation and inﬂammatory responses in animals.28 Other
studies have demonstrated that both membrane-type recep-
tor activations are involved in the regulation of the CatK and
MMP-2/-9 expressions in macrophages and endothelial cells
Figure 7 CatK inhibition ameliorated the inﬂammatory actions of the injured muscles of the CONT (vehicle), LKI (low-dose CatK inhibitor), and HKI
(high-dose CatK inhibitor) mice at Day 3 after cardiotoxin injection. (A–C) Representative images of the immunostaining and combined quantitative
data show the numbers of inﬁltrated macrophages (CD68+ cells) and leucocytes (CD45+ cells) in the injured gastrocnemius of the three experimental
groups. Scale bar: A, 50 μm; B, 25 μm. (D–G) Quantitative real-time polymerase chain reaction data show the levels of TLR-2, TLR-4, TNF-α, and MCP-1
in the non-injured and injured muscles of the three experimental groups. Results are the mean ± SD (n = 6). *P < 0.05, **P < 0.01 vs. the correspond-
ing control groups by Student’s t-test or one-way analysis of covariance followed by Tukey post hoc tests. NS, not signiﬁcant.
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by several intracellular signalling pathways.43,44 Our present
experiments revealed that the increased levels of TLR-2 and
TLR-4 gene expression induced by CTX were alleviated by
CatK inhibition in vivo. Thus, the ability of CatK inhibition to
abolish TLR-2/-4-mediated MMP-2/-9 expression and activi-
ties is attributable to the contribution of CatK inhibition to
the muscle beneﬁts in CatK/ mice or ONO-KK1-300-01-
treated CatK+/+ mice under our experimental conditions.
Given that the comprehensive reviews have focused on
the roles of a cathepsin/cystatin system in cardiovascular
and inﬂammatory cell events,11,13 it is notable that CatK
seems to be of particular importance for cell apoptosis in
the cardiovascular repair process. Among the members of
the lysosomal cathepsin family, CatC has been shown to facil-
itate lysosomal rupture and necrotic cell death.45 In addition,
in vitro and in vivo experiments revealed that silencing of
CatK inhibited cardiac cell apoptosis via reductions of mito-
chondrial cytochrome c production and proapoptotic mole-
cule expression.24 Sun et al.43 showed that aneurysm
lesions from CatK/ mice contained fewer TUNEL+ apoptotic
cells than did CatK+/+ mice.46 They also reported that a deﬁ-
ciency in the endogenous cathepsin inhibitor cystatin C re-
sulted in epidermal hyperplasia via the modulation of
epithelial apoptosis.47 Our present results showed that the
muscle lesions in CatK/ mice had lower numbers of TUNEL+
apoptotic cells compared with the muscle lesions of the con-
trol mice. ONO-KK1-300-01 treatment also suppressed the
cell apoptosis of the injured skeletal muscle tissues in the
CatK+/+ mice. In vitro, CatK inhibition suppressed the CTX-
induced apoptosis of matured C2C12 cells. Because CTX in-
jury induces CatK expression and activation in vivo and
in vitro, we propose that CatK modulates skeletal muscle
Figure 8 CatK inhibition prevented cardiotoxin (CTX)-induced C2C12 cell apoptosis. (A) Representative images of morphological change of the differ-
entiated C2C12 cells cultured in the presence and absence of cardiotoxin (0.5 μM) alone and in combination with the CatK inhibitor ONO-KK1-300-01
(25 μM) for 24 h. (B) CatK inhibition suppressed the C2C12 cell-conditioned medium lactate dehydrogenase (LDH) levels in response to CTX (n = 6). (C)
Representative images of terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) immunoﬂuorescence and combined quantitative data
for the TUNEL+ cell numbers (n = 5). Scale bar, 100 μm. (D, E) Representative images of the simple western blots and combined quantitative data show
the levels of CatK, caspase-3, and BAX proteins in the lysates of the experimental groups (control, CTX, and CTX + CatK-I; n = 3 per group). Results are
the mean ± SD. *P < 0.05, **P < 0.01 vs. the corresponding controls by one-way analysis of covariance followed by Tukey post hoc tests.
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remodelling/loss and dysfunction in a CTX-injury state
through its ability to activate muscle apoptosis. BAX/Bcl-2
and caspase-3/-8 molecules have been widely accepted as
the critical modulators of various types of cell apoptosis.
Our present ﬁndings indicate that genetic and pharmacologi-
cal inhibitions of CatK reduced the protein levels of cleaved
caspase-3 and cleaved caspase-8 and the ratio of BAX to
Bcl-2 in the muscle lesions. We also observed that the expres-
sions of the TLR-4 and TLR-2 genes were decreased in injured
muscles of CatK/ mice and CatK+/+ mice treated with CatK-
I. In C2C12 cells, we have shown that CatK inhibition sup-
pressed CTX-induced BAX and caspase-3 protein expressions.
Several previous lines of investigation have demonstrated
that TLR-2 and TLR-4 are required for cell apoptosis via the
activation of the caspase-8 and nuclear factor-κB signalling
pathway.48,49 Further, it has been shown that TLR-2/-4 deﬁ-
ciency prevents oxygen-induced endothelial apoptosis and
vascular degeneration50 Caspase-8 has been shown to be a
key mediator in the interaction between the TLR-2/-4 axis.51
Taken together, these ﬁndings suggest that the attenuation
of cell apoptosis by CatK inhibition via the improvement of
TLR-2/-4-mediated pro-apoptotic and anti-apoptotic mole-
cule expressions may represent a common mechanism un-
derlying the reduction of injury-induced skeletal muscle
remodelling and ﬁbrosis under our experimental conditions.
Several limitations should be considered. First, the in vitro
model used in the present study is not a proper model to rep-
resent CTX-induced muscle ﬁbre injury in vitro, especially
considering that muscle ﬁbres in vivo are generally replaced
by ﬁbrotic/connective tissue and show a high level of inﬂam-
matory cells that interact with muscle cells to reduce muscle
cell function. Thus, our C2C12 cell experiments may not fully
mimic all the muscle changes to address the related
molecular mechanism in vivo. Second, CTX-induced muscle
injury model is not closely relevant to aging-related muscle
disease but rather to acute injury-related muscle disease.
Third, here, 10-week-old young male CatK+/+ and CatK/
mice were applied to the CTX-induced muscle injury
model to study the role of CatK in age-related muscle dis-
ease (i.e. sarcopenia/dynapenia). Aged both genotype mice
will be more suitable to investigate our hypothesis. Fourth,
we could not to deign to conﬁrm our ﬁndings in generalizabil-
ity to aging. Further studies should be look at aged animals
and humans. Additionally, in 2015, Fry and colleagues demon-
strated that inducible depletion of satellite cells in adult, sed-
entary mice impairs muscle regenerative capacity without
affecting sarcopenia.52 Thus, injury-induced muscle apoptosis
appears to be one obvious contributory mechanism to age-
related muscle loss but not the be-all and end-all. Fifth, little
or nothing is known about muscle in pycnodysostosis—the
human disease caused by CatK deﬁciency. Sixth, it has been
reported that ONO-KK1-300-01, N-{3-[(2Z)-2-(3-methyl-1,3-
thiazolidin-2-ylidene)hydrazino]-2,3-dioxo-1-tetrahydro-2H-
pyran-4-ylpropyl}cycloheptanecarboxamide hydrochloride,
and ONO-5334, N-((1S)-3-{(2Z)-2-[(4R)-3,4-dimethyl-1,3-
thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-(tetrahydro-2H-py-
ran-4-yl)propyl)cycloheptanecarboxamide, were synthesized in
ONO Pharmaceutical Co., Ltd. (Osaka, Japan).53,54 The former
is hydrochloride, and the latter has one more methyl group.53,54
Both CatK inhibitors have shown to ameliorate bone density
and/or bone resporption in several animal metabolic bone dis-
ease models.53,54 Similarly, the data from a small scale clinical
studies reported that ONO-5334 mitigated bone mineral den-
sity without the change in bone size.55 However, we have
pointed out one large clinical LOFT trial (the Long-Term
Odanacatib Fracture Trail) that was started to treat with ONO-
5334 post-menopausal osteoporosis.56 Unfortunately, this trial
has led to discontinuation of the development of odanacatib
for the treatment of osteoporosis due to cardiovascular side
effects.56 These negative data of CatK inhibitor prompt clini-
cians to look at some muscle/sarcopenia endpoints in existing
clinical trial data.
Conclusions
The ability of injury to increase skeletal muscle apoptosis
have been shown to contribute to the age-associated muscle
weakness and wasting in a wide range of mammals. However,
the molecular mechanisms by which injury causes muscle cell
apoptosis and remodelling are poorly understood. The ex-
pressions of the CatK gene and protein are known to be in-
creased in injured muscle tissues. Here, CatK deletion was
shown to prevent acute CTX-induced muscle apoptosis, re-
modelling and ﬁbrosis and muscle dysfunction. The pharma-
cological inhibition of CatK mimics the protective effects of
genetic CatK ablation on skeletal muscle. It seems that selec-
tive CatK inhibitors may have potential utility in the treat-
ment or control of injury-related skeletal muscle apoptosis,
remodelling and dysfunction in age-associated muscle disor-
ders. However, it remains to be determined whether pharma-
cological CatK inhibition has muscle beneﬁts in humans, and
whether or not, this will not be hampered by other unwanted
side effects. Further studies will be also needed to investigate
these issues.
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Table S1. Primer sequences for mice used for quantitative
real-time PCR
Figure S1. Expressions of matrix metalloproteinase (MMP)
and cathepsin family genes in the muscles of CatK+/+
mice at the indicated time points after cardiotoxin (CTX)
injection. A: Photos of both gastrocnemius mass and rep-
resentative microscopy images of H&E staining of the
non-injured and injured muscles of CatK+/+ mice on days
3 and 14 after injury. B–D: Quantitative real-time PCR data
show the levels of CatK, CatS, CatL, MMP-2, MMP-9, tis-
sue inhibitor of metalloproteinase (TIMP)-1, and TIMP-2
at days 0, 3, 7, and 14 after injury. Results are the
mean ± SD (n = 6). E: A representative result of gelatin
zymography shows the levels of MMP-2 and MMP-9
gelatinolytic activities of the non-injured and injured mus-
cles of CatK+/+ mice at day 3 after CTX injection.
*p < 0.05, **p < 0.01 vs. the corresponding day 0 by
one-way ANOVA followed by Tukey post hoc tests.
Figure S2. Effects of CatK inhibition on the levels of cas-
pase-3 and cleaved caspase-3 in the muscles. A-B: Repre-
sentative images of Western blots and the combined
quantitative data show the ratio of cleaved caspase-3 to
caspase-3 band intensities in the injured muscles of CatK+/
+ and CatK/ mice. C-D: Representative images of Western
blots and the combined quantitative data show the ratio of
cleaved caspase-3 to caspase-3 band intensities in the in-
jured muscles of CONT, LKI (low-dose CatK inhibitor) and
HKI (high-dose CatK inhibitor) mice.
Figure S3. The gene expressions of cathepsin and MMP
families in the skeletal muscles of mice of both genotypes
at day 3 after injury. A–C: Quantitative real-time PCR data
show the levels of CatS, CatL, MMP-2, MMP-9, TIMP-1,
and TIMP-2 genes in the non-injured and injured gastrocne-
mius muscles of mice of both genotypes. Results are the
mean ± SD (n = 5). D,E: Representative images of gelatin
zymography and combined quantitative data show the
gelatinolytic activities of MMP-2 and MMP-9 in the non-in-
jured and injured gastrocnemius muscles of mice in both ex-
perimental groups. Results are the mean ± SD (n = 5).
*p < 0.05, **p < 0.01 vs. the corresponding control groups
by Student’s t-test or one-way ANOVA followed by Tukey
post hoc tests. NS: not signiﬁcant.
Figure S4. Evaluation of cathepsin and MMP gene expres-
sions in the non-injured and injured gastrocnemius muscles
of CatK+/+ mice treated with vehicle (0.5% carboxymethyl-
cellulose; CONT mice) or a low or high dose of the speciﬁc
CatK inhibitor ONO-KK1–300-01 (3 mg/kg, LKI mice;
30 mg/kg, HKI mice) at day 3 after CTX injury. A–D: Quanti-
tative real-time PCR data show the levels of CatS, CatK,
CatL, MMP-2, MMP-9, TIMP-1, and TIMP-2 in the non-in-
jured and injured muscles of the three experimental groups.
Results are the mean ± SD (n = 6). E,F: Representative im-
ages of gelatin zymography and combined quantitative data
show the gelatinolytic activities of MMP-2 and MMP-9 of
the injured gastrocnemius in the three experimental groups
(n = 4). *p < 0.05, **p < 0.01 vs. the corresponding control
groups by Student’s t-test or one-way ANOVA followed by
Tukey post hoc tests. NS: not signiﬁcant.
Figure S5. CatK inhibition prevented CTX-induced muscle
function. A: Grip strength was measured over 5 times in each
mouse on 0, 3 and 14 days after CTX injury and averaged to
obtain the grip strength for each time point. B: Workload in
the vertical direction was calculated in consideration of the
weight of the mouse (= weight × gravitational acceleration ×
mileage in the vertical direction). C,D: Running time and dis-
tance were calculated from the product of running time and
speed. All items were expressed as the ratio of observed
values to data on day 0 before CTX injection. Results are the
mean ± SD (n = 3). *P < 0.05, vs. the corresponding controls
by 2-way repeated-measures ANOVA and Bonferroni post
hoc tests.
Figure S6. Changes in the expression of CatK mRNA induced
by CTX in a time- and dose-dependent manner. A:Microscopy
images and quantitative real-time PCR data show the levels of
CatK mRNA in the serum-free medium at the indicated time
points. B: Representative images and quantitative real-time
PCR data show changes in the CTX-induced CatK mRNA ex-
pression over time. C: Representative images and quantitative
real-time PCR data show changes in the CTX-induced CatK
mRNA expression with dose. Scale bars: A, 50 μm.
*p < 0.05, **p < 0.01 vs. the corresponding control groups
by Student’s t-test or one-way ANOVA followed by Tukey post
hoc tests. NS: not signiﬁcant.
Conﬂict of interest
M.K. received research support from the ONO Pharmaceuti-
cal Co., Ltd. (Osaka, Japan). However, ONO had no involve-
ment in the process of manuscript development and did
not inﬂuence the content of this manuscript in any manner.
The other authors declare no conﬂicts of interest.
Author contribution statement
S.O.: Major contributor to the collection and assembly of
data; manuscript writing; morphological analysis; western
Cathepsin K deﬁciency protects muscle injury 173
Journal of Cachexia, Sarcopenia and Muscle 2018; 9: 160–175
DOI: 10.1002/jcsm.12248
blotting and real-time PCR analysis; collection and assembly
of samples and data, data analysis and interpretation. X.W.
C.: Major contributor to the collection and assembly of data;
ﬁnancial support; conception, design and editing of the man-
uscript. A.I. and H.G.: Collection and assembly of samples and
data, data analysis and interpretation. L.H., L.P., C.Y., H.G.,W.
X., G.Z., L.Y., G.Y., and K.K.: CatK genotyping and bleeding. H.
U. and G.P.S.: Reviewed/edited the manuscript. M.K.: Finan-
cial support; conception, design and editing of the
manuscript.
References
1. Arthur ST, Cooley ID. The effect of physio-
logical stimuli on sarcopenia; impact of
Notch and Wnt signaling on impaired aged
skeletal muscle repair. Int J Biol Sci
2012;8:731–760.
2. Girgis CM, Baldock PA, Downes M. Vitamin
D, muscle and bone: integrating effects in
development, aging and injury. Mol Cell
Endocrinol 2015;410:3–10.
3. Peake J, Della Gatta P, Cameron-Smith D.
Aging and its effects on inﬂammation in
skeletal muscle at rest and following
exercise-induced muscle injury. Am J Phys-
iol Regul Integr Comp Physiol 2010;298:
R1485–R1495.
4. Dahiya S, Bhatnagar S, Hindi SM, Jiang C,
Paul PK, Kuang S, et al. Elevated levels of
active matrix metalloproteinase-9 cause
hypertrophy in skeletal muscle of normal
and dystrophin-deﬁcient mdx mice. Hum
Mol Genet 2011;20:4345–4359.
5. Urso ML, Wang R, Zambraski EJ, Liang BT.
Adenosine A 3 receptor stimulation re-
duces muscle injury following physical
trauma and is associated with alterations
in the MMP/TIMP response. J Appl Physiol
2010;112:658–670.
6. Zimowska M, Olszynski KH, Swierczynska
M, Streminska W, Ciemerych MA. Decrease
of MMP-9 activity improves soleus muscle
regeneration. Tissue Eng Part A
2012;18:1183–1192.
7. Bellayr I, Holden K, Mu X, Pan H, Li Y. Ma-
trix metalloproteinase inhibition negatively
affects muscle stem cell behavior. Int J Clin
Exp Pathol 6:124–141.
8. Ogura Y, Tajrishi MM, Sato S, Hindi SM,
Kumar A. Therapeutic potential of matrix
metalloproteinases in Duchenne muscu-
lar dystrophy. Front Cell Dev Biol 2014;
2:1–11.
9. Yeghiazaryan M, Zybura-Broda K, Cabaj A,
Wlodarczyk J, Slawinska U, Rylski M, et al.
Fine-structural distribution of MMP-2 and
MMP-9 activities in the rat skeletal muscle
upon training: a study by high-resolution in
situ zymography. Histochem Cell Biol
2010;138:75–87.
10. Turk B, Turk V, Turk D. Structural and func-
tional aspects of papain-like cysteine pro-
teinases and their protein inhibitors. Biol
Chem 1997;378:141–150.
11. Cheng XW, Huang Z, Kuzuya M, Okumura
K, Murohara T. Cysteine protease cathep-
sins in atherosclerosis-based vascular dis-
ease and its complications. Hypertension
2011;58:978–986.
12. Turk B, Turk D, Turk V. Lysosomal cysteine
proteases: more than scavengers. Biochim
Biophys Acta 2000;1477:98–111.
13. Cheng XW, Shi GP, Kuzuya M, Sasaki T,
Okumura K, Murohara T. Role for cyste-
ine protease cathepsins in heart disease:
focus on biology and mechanisms with
clinical implication. Circulation 2012;
125:1551–1562.
14. Song H, Jiang H, Nan Y, Cheng X. Degesting
the remodeled cardiovascular wall: role of
cysteinyl cathepsins in cardiovascular disease.
Minerva Cardioangiol 2015;63:525–531.
15. Cheng XW, Sasaki T, Kuzuya M. The role of
cysteinyl cathepsins in venous disorders.
Thromb Haemost 2014;112:216–218.
16. Wu H, Cheng XW, Hu L, Takeshita K, Hu C,
Du Q, et al. Cathepsin S activity controls
injury-related vascular repair in mice via
the TLR2-mediated p38MAPK and
PI3K-Akt/p-HDAC6 signaling pathway.
Arterioscler Thromb Vasc Biol 2016;
36:1549–1557.
17. Wu H, Cheng XW, Hu L, Hao CN, Hayashi
M, Takeshita K, et al. Renin inhibition re-
duces atherosclerotic plaque neovessel for-
mation and regresses advanced
atherosclerotic plaques. Atherosclerosis
2014;237:739–747.
18. Li X, Li Y, Jin J, Jin D, Cui L, Rei Y, et al. In-
creased serum cathepsin K in patients with
coronary artery disease. Yonsei Med J
2014;55:912–919.
19. Zhao G, Li Y, Cui L, Li X, Jin Z, Han X, et al.
Increased circulating cathepsin K in pa-
tients with chronic heart failure. PLoS One
2015;10: e0136093.
20. Izumi Y, Hayashi M, Morimoto R, Cheng
XW,Wu H, Ishii H, et al. Impact of circulat-
ing cathepsin K on the coronary calciﬁca-
tion and the clinical outcome in chronic
kidney disease patients. Heart Vessels
2017;31:6–14.
21. Li X, Cheng XW, Hu L,Wu H, Guo P, Hao CN,
et al. Cathepsin S activity controls
ischemia-induced neovascularization in
mice. Int J Cardiol 2015;183:198–208.
22. Cheng XW, Murohara T, Kuzuya M, Izawa
H, Sasaki T, Obata K, et al. Superoxide-de-
pendent cathepsin activation is associated
with hypertensive myocardial remodeling
and represents a target for angiotensin II
type 1 receptor blocker treatment. Am J
Pathol 2008;173:358–369.
23. Cheng XW, Obata K, Kuzuya M, Izawa H,
Nakamura K, Asai E, et al. Elastolytic ca-
thepsin induction/activation system exists
in myocardium and is upregulated in hy-
pertensive heart failure. Hypertension
2006;48:979–987.
24. Hua Y, Zhang Y, Dolence J, Shi GP, Ren J,
Nair S. Cathepsin K knockout mitigates
high-fat diet-induced cardiac hypertrophy
and contractile dysfunction. Diabetes
2013;62:498–509.
25. Li Z, Hou WS, Bromme D. Collagenolytic ac-
tivity of cathepsin K is speciﬁcally modu-
lated by cartilage-resident chondroitin
sulfates. Biochemistry 2000;39:529–536.
26. Cheng XW, Kuzuya M, Sasaki T, Arakawa K,
Kanda S, Sumi D, et al. Increased expres-
sion of elastolytic cysteine proteases, ca-
thepsins S and K, in the neointima of
balloon-injured rat carotid arteries. Am J
Pathol 2004;164:243–251.
27. Sukhova GK, Shi GP, Simon DI, Chapman
HA, Libby P. Expression of the elastolytic
cathepsins S and K in human atheroma
and regulation of their production in
smooth muscle cells. J Clin Invest
1998;102:576–583.
28. Hu L, Cheng XW, Song H, Inoue A, Jiang H,
Li X, et al. Cathepsin K activity controls
injury-related vascular repair in mice. Hy-
pertension 2014;63:607–615.
29. Jiang H, Cheng XW, Shi GP, Hu L, Inoue A,
Yamamura Y, et al. Cathepsin K-mediated
Notch1 activation contributes to neovascu-
larization in response to hypoxia. Nat
Commun 2014;5:3838.
30. Reiser J, Adair B, Reinheckel T. Specialized
roles for cysteine cathepsins in health and
disease. J Clin Invest 2010;120:3421–3431.
31. Inoue A, Cheng XW, Huang Z, Hu L,
Kikuchi R, Jiang H, et al. Exercise restores
muscle stem cell mobilization, regenera-
tive capacity and muscle metabolic alter-
ations via adiponectin/AdipoR1 activation
in SAMP10 mice. J Cachexia Sarcopenia
Muscle 2016 Nov 29;https://doi.org/
10.1002/jcsm.12166.
32. Cheng XW, Kuzuya M, Nakamura K, Di Q,
Liu Z, Sasaki T, et al. Localization of cyste-
ine protease, cathepsin S, to the surface
of vascular smooth muscle cells by associa-
tion with integrin alphanubeta3. Am J
Pathol 2006;168:685–694.
33. Kuzuya M, Nakamura K, Sasaki T, Cheng
XW, Itohara S, Iguchi A. Effect of MMP-
2 deﬁciency on atherosclerotic lesion
formation in apoE-deﬁcient mice.
Arterioscler Thromb Vasc Biol 2006;
26:1120–1125.
34. Cheng XW, Kuzuya M, Kim W, Song H,
Hu L, Inoue A, et al. Exercise training
stimulates ischemia-induced neovasculari-
zation via phosphatidylinositol 3-kinase/
Akt-dependent hypoxia-induced factor-1
alpha reactivation in mice of advanced
age. Circulation 2010;122:707–716.
35. Cheng XW, Kuzuya M, Nakamura K, Maeda
K, Tsuzuki M, Kim W, et al. Mechanisms un-
derlying the impairment of ischemia-
174 S. Ogasawara et al.
Journal of Cachexia, Sarcopenia and Muscle 2018; 9: 160–175
DOI: 10.1002/jcsm.12248
induced neovascularization in matrix me-
talloproteinase 2-deﬁcient mice. Circ Res
2007;100:904–913.
36. Harris VM. Protein detection by Simple
Western™ analysis. Methods Mol Biol
2015;1312:465–468.
37. Kimura K, Cheng XW, Inoue A, Hu L, Koike
T, Kuzuya M. β-Hydroxy-β-methylbutyrate
facilitates PI3K/Akt-dependent mammalian
target of rapamycin and FoxO1/3a phos-
phorylations and alleviates tumor necrosis
factor alpha/interferon gamma-induced
MuRF-1 expression in C2C12 cells. Nutr
Res 2014;34:368–374.
38. Liu N, Nelson BR, Bezprozvannaya S,
Shelton JM, Richardson JA, Bassel-Duby
R, et al. Requirement of MEF2A, C, and
D for skeletal muscle regeneration. Proc
Natl Acad Sci U S A 2014;
111:4109–4114.
39. Mnafgui K, Hajji R, Derbali F, Gammoudi A,
Khabbabi G, Elleﬁ H, et al. Anti-inﬂamma-
tory, antithrombotic and cardiac remodel-
ing preventive effects of eugenol in
isoproterenol-induced myocardial infarc-
tion in Wistar rat. Cardiovasc Toxicol
2016;16:336–344.
40. Saxena A, Rauch U, Berg KE, Andersson L,
Hollender L, Carlsson AM, et al. The vascu-
lar repair process after injury of the carotid
artery is regulated by IL-1RI and MyD88
signalling. Cardiovasc Res
2016;91:350–357.
41. Kim F, Pham M, Luttrell I, Bannerman DD,
Tupper J, Thaler J, et al. Toll-like receptor-
4 mediates vascular inﬂammation and in-
sulin resistance in diet-induced obesity.
Circ Res 2007;100:1589–1596.
42. Mullick AE, Tobias PS, Curtiss LK. Modula-
tion of atherosclerosis in mice by Toll-like
receptor 2. J Clin Invest 2005;
115:3149–3156.
43. Sun Y, Ishibashi M, Seimon T, Lee M,
Sharma SM, Fitzgerald KA, et al. Free
cholesterol accumulation in macrophage
membranes activates Toll-like receptors
and p38 mitogen-activated protein kinase
and induces cathepsin K. Circ Res
2009;104:455–465.
44. Cheng XW, Song H, Sasaki T, Hu L, Inoue A,
Bando YK, et al. Angiotensin type 1 recep-
tor blocker reduces intimal neovasculariza-
tion and plaque growth in apolipoprotein
E-deﬁcient mice. Hypertension 2011;
57:981–989.
45. Brojatsch J, Lima H, Kar AK, Jacobson LS,
Muehlbauer SM, Chandran K, et al. A pro-
teolytic cascade controls lysosome rupture
and necrotic cell death mediated by
lysosome-destabilizing adjuvants. PLoS
One 2014;9: e95032.
46. Sun J, Sukhova GK, Zhang J, Chen H,
Sjoberg S, Libby P, et al. Cathepsin K deﬁ-
ciency reduces elastase perfusion-induced
abdominal aortic aneurysms in mice.
Arterioscler Thromb Vasc Biol 2012;
32:15–23.
47. Yu W, Liu J, Shi MA, Wang J, Xiang M,
Kitamoto S, et al. Cystatin C deﬁciency pro-
motes epidermal dysplasia in K14-HPV16
transgenic mice. PLoS One 2010;5: e13973.
48. Li H, Zhu C, Wang B, Zhu W, Feng Y, Du F,
et al. 17β-Estradiol protects the retinal
nerve cells suppressing TLR2 mediated
immune-inﬂammation and apoptosis from
oxidative stress insult independent of
PI3K. J Mol Neurosci 2016;60:195–204.
49. Aliprantis AO, Yang RB,Weiss DS, Godowski
P, Zychlinsky A. The apoptotic signaling
pathway activated by Toll-like receptor-2.
EMBO J 2000;19:3325–3336.
50. He C, Lai P, Wang J, Zhou T, Huang Z, Zhou
L, et al. TLR2/4 deﬁciency prevents oxygen-
induced vascular degeneration and pro-
motes revascularization by downregulating
IL-17 in the retina. Sci Rep 2016;6: 27739.
51. Lemmers B, Salmena L, Bidere N, Su H,
Matysiak-Zablocki E, Murakami K, et al.
Essential role for caspase-8 in Toll-like re-
ceptors and NFkappaB signaling. J Biol
Chem 2007;282:7416–7423.
52. Fry CS, Lee JD, Mula J, Kirby TJ, Jackson
JR, Liu F, et al. Inducible depletion of
satellite cells in adult, sedentary mice
impairs muscle regenerative capacity
without affecting sarcopenia. Nat Med
2015;21:76–80.
53. Ochi Y, Yamada H, Mori H, Kawada N,
Tanaka M, Imagawa A, et al. Combina-
tion therapy with ONO-KK1-300-01, a
cathepsin K inhibitor, and parathyroid
hormone results in additive beneﬁcial
effect on bone mineral density in ovari-
ectomized rats. J Bone Miner Metab
2016;34:33–40.
54. Ochi Y, Yamada H, Mori H, Nakanishi Y,
Nishikawa S, Kayasuga R, et al. Effects of
ONO-5334, a novel orally-active inhibitor
of cathepsin K, on bone metabolism. Bone
2011;49:1351–1356.
55. Engelke K, Nagase S, Fuerst T, Small M,
Kuwayama T, et al. The effect of the ca-
thepsin K inhibitor ONO-5334 on trabecu-
lar and cortical bone in postmenopausal
osteoporosis: the OCEAN study. J Bone
Miner Res 2014;29:629–638.
56. Bone HG, Dempster DW, Eisman JA, Green-
span SL, McClung MR, Nakamura T, et al.
Odanacatib for the treatment of postmen-
opausal osteoporosis: development history
and design and participant characteristics
of LOFT, the Long-Term Odanacatib
Fracture Trial. Osteoporos Int 2014;
26:699–712.
57. von Haehling S, Morley JE, Coats AJ, Anker
SD. Ethical guidelines for publishing in the
Journal of Cachexia, Sarcopenia and Mus-
cle: update 2015. J Cachexia Sarcopenia
Muscle 2015;6:315–316.
Cathepsin K deﬁciency protects muscle injury 175
Journal of Cachexia, Sarcopenia and Muscle 2018; 9: 160–175
DOI: 10.1002/jcsm.12248
